Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)‘s stock had its “buy” rating reiterated by analysts at Needham & Company LLC in a research note issued on Tuesday. They presently have a $32.00 target price on the stock. Needham & Company LLC’s price target would indicate a potential upside of 25.69% from the company’s previous close.

The analysts wrote, “Rhythm reported 3Q17 financial results and we spoke w/ mgmt for an update. Enrollment in Phase 3 setmelanotide trial in POMC Deficiency is still expected to be completed by YE17. We assume top-line results in early 2019 (unch) and continue to expect a positive outcome. Mgmt also reiterated guidance for intiation of Phase 3 setmelanotide trial in LepR Deficiency by YE17. Data in a small number of patients with POMC or LepR Deficiency were remarkably strong and are the basis for our enthusiasm for the drug and the stock. We await data from Phase 2 trials in Alstrom Syndrome and POMC Epigenetic/ Heterozygous mutation patients in early 2018. A favorable outcome would add meaningfully to peak sales potential. BUY.””

Other research analysts also recently issued reports about the company. Morgan Stanley began coverage on Rhythm Pharmaceuticals in a report on Monday, October 30th. They issued an “equal weight” rating and a $23.00 price target for the company. Bank of America Corporation began coverage on Rhythm Pharmaceuticals in a report on Monday, October 30th. They issued a “buy” rating and a $30.00 price target for the company. Finally, Cowen and Company began coverage on Rhythm Pharmaceuticals in a report on Monday, October 30th. They issued an “outperform” rating and a $40.00 price target for the company.

Rhythm Pharmaceuticals (NASDAQ RYTM) traded up $1.25 on Tuesday, reaching $25.46. The company’s stock had a trading volume of 100,300 shares, compared to its average volume of 284,493. Rhythm Pharmaceuticals has a 52 week low of $21.38 and a 52 week high of $33.81.

ILLEGAL ACTIVITY NOTICE: “Rhythm Pharmaceuticals, Inc. (RYTM) Stock Rating Reaffirmed by Needham & Company LLC” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.americanbankingnews.com/2017/11/14/rhythm-pharmaceuticals-inc-rytm-stock-rating-reaffirmed-by-needham-company-llc.html.

In other Rhythm Pharmaceuticals news, insider James E. Flynn purchased 355,000 shares of the stock in a transaction dated Tuesday, October 10th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $6,035,000.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder S.A. Ipsen purchased 20,000 shares of the stock in a transaction dated Tuesday, October 10th. The shares were acquired at an average price of $17.00 per share, with a total value of $340,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 1,285,000 shares of company stock valued at $21,845,000.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.

Receive News & Ratings for Rhythm Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.